查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602171

治疗药物监测市场：按产品、技术、药物类别和最终用户 - 2025-2030 年全球预测

Therapeutic Drug Monitoring Market by Product (Consumables, Data Management Services, Equipment), Technology (Chromatography-MS, Immunoassays, Proteomic Technologies), Drug Class, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年治疗药物监测市场价值为37.9亿美元，预计到2024年将达到43.8亿美元，复合年增长率为16.11%，到2030年将达到107.8亿美元。

治疗药物监测 (TDM) 涉及测量血流中的药物浓度，以优化剂量并最大限度地提高治疗效果，同时最大限度地降低毒性。由于患者在药物吸收、分布、代谢和排泄方面存在差异，因此需要个别化给药方案，因此需要 TDM。 TDM的应用主要包括治疗范围较窄的药物，如抗惊厥药、抗生素和免疫抑制剂，在个人化医疗中至关重要，可确保有效治疗，同时最大限度地减少副作用。最终使用范围主要延伸到医院、实验室和临床环境[药物动力学单位]，我们正在积极努力提高治疗的有效性和安全性。 TDM 市场的成长受到慢性病盛行率上升、药物基因组学进步以及对个人化医疗日益关注等因素的影响，但也受到检测成本上升、严格的法律规范以及对高技能专业人员的需求等问题的影响。此外，TDM 还提供了潜在的机会，可以透过就地检验的创新和预测性监测人工智慧的集成，为即时药物监测和改善患者治疗结果铺平道路。为了利用这些机会，相关人员正在投资研发以创建具有成本效益的 TDM 解决方案，与生物技术公司和医疗机构建立策略伙伴关係，并扩大覆盖范围和适应性。市场限制包括技术限制和欠发达地区缺乏认识，但非侵入性采样和快速诊断技术的进步有可能显着克服这些挑战。最有前景的技术创新领域包括开发便携式、易于使用的监控设备和增强的资料分析能力，以提供更准确和可操作的见解。总体而言，对技术创新、可负担性和以患者为中心的解决方案的策略重点对于持续的市场成长和抓住动态治疗药物监测领域的新机会至关重要。

主要市场统计
基准年[2023] 37.9亿美元
预测年份 [2024] 43.8亿美元
预测年份 [2030] 107.8亿美元
复合年增长率（%） 16.11%

市场动态：快速发展的治疗药物监测市场的关键市场洞察

供需的动态交互作用正在改变治疗药物监测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 个人化医疗需求不断成长
    • 在各个治疗领域更常采用治疗药物监测
    • 在固态器官移植患者的使用和重要性不断增加
  • 市场限制因素
    • 报销政策不完善
    • 需要昂贵的资本投资
  • 市场机会
    • 开发中国家治疗药物监测的未来前景
    • 免疫检测和其他治疗药物监测技术的进展
  • 市场挑战
    • 临床问题和熟练实验室技术人员的短缺

波特五力：驾驭治疗药物监测市场的策略工具

波特的五力架构是了解治疗药物监测市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解治疗药物监测市场的外部影响

外部宏观环境因素在塑造治疗药物监测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解治疗药物监测市场的竞争状况

对治疗药物监测市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵治疗监测市场供应商的绩效评估

FPNV定位矩阵是评估治疗药物监测市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对个人化医疗的需求不断增加
      • 在各个治疗领域更常采用治疗药物监测
      • 在固态器官移植患者的使用和重要性不断增加
    • 抑制因素
      • 退款政策不佳
      • 需要大量资本投资
    • 机会
      • 开发中国家治疗药物监测的未来前景
      • 免疫检测和其他治疗药物监测技术的进展
    • 任务
      • 临床挑战和熟练实验室技术人员的短缺
  • 市场区隔分析
    • 产品：对高效药物管理的资料管理服务的需求不断增长
    • 最终用户：医院的需求不断增长，准确的药品管理至关重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章治疗药物监测市场：副产品

  • 消耗品
  • 资料管理服务
  • 装置
    • 层析法和质谱检测器
    • 临床生化分析仪
    • 免疫检测分析仪

第七章治疗药物监测市场：依技术分类

  • 层析法-MS
    • GC-MS
    • LC-MS
  • 免疫检测
    • 化学冷光免疫检测
    • 比色免疫检测
    • 萤光免疫分析法
    • 免疫检测
  • 蛋白质体技术

第八章按药物类别分類的治疗药物监测市场

  • 抗心律不整药物
  • 抗生素
  • 抗癫痫药
  • 支气管扩张剂
  • 免疫抑制药物
  • 精神药物

第九章 治疗药物监测市场：依最终使用者分类

  • 医院实验室
  • 私人实验室

第十章美洲治疗药物监测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区治疗药物监测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的治疗药物监测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Capitainer 宣布与阿斯特捷利康建立合作关係。
    • Novo Holdings 投资蛋白质体学技术公司 Evosep。
    • AegirBio AB 已与 Atlas Special Opportunities, LLC 签署协议，发行 5,500 万瑞典克朗带认股权证的可转换债券，以加强对 TDM、唾液样本采集等领域的投资。
    • 用于治疗药物监测分析的临床 LC-MS 方法。
    • Boditech Med取得4个TDM产品的出口许可。
    • Pace 检测戴奥辛和二苯并呋喃的 GC-MS/MS 技术已获得 EPA核准。
    • Bio-Rad 扩展了其用于生物分析和药物监测的抗个体遗传型抗体系列。
    • Beckman Coulter 和 Saladax Biomedical 在抗精神病药物监测方面合作。
    • Ampersand Capital Partners 投资了领先的 SIFT-MS解决方案供应商Syft Technologies。

公司名单

  • apDia Group
  • Cambridge Life Sciences Limited
  • Danaher Corporation
  • ARK Diagnostics, Inc.
  • Assay Genie
  • DiaSorin SpA
  • Merck KGaA
  • Grifols, SA
  • Siemens Healthineers AG
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • DiaSystem Scandinavia AB
  • R-Biopharm AG
  • Bio-Rad Laboratories, Inc.
  • Krishgen Biosystems
  • HU Group Holdings, Inc.
  • Buhlmann Laboratories AG
  • Myriad Genetics, Inc.
  • Theradiag SA
  • Randox Laboratories, Ltd.
  • Thermo Fisher Scientific, Inc.
  • Tecan Trading AG
  • OneCare Media, LLC
  • Chromsystems Instruments & Chemicals GmbH
  • Agilent Technologies, Inc.
  • Eagle Biosciences, Inc.
  • Svar Life Science AB
  • Sekisui Chemical Co Ltd.
  • Neoteryx, LLC by Trajan Group
  • Veolia Group
  • bioMerieux SA
  • ARUP Laboratories
  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Exagen Inc.
Product Code: MRR-A77F2EE7AB43

The Therapeutic Drug Monitoring Market was valued at USD 3.79 billion in 2023, expected to reach USD 4.38 billion in 2024, and is projected to grow at a CAGR of 16.11%, to USD 10.78 billion by 2030.

Therapeutic Drug Monitoring (TDM) involves measuring drug concentrations in the bloodstream to optimize dosage and maximize therapeutic efficacy while minimizing toxicity. The necessity of TDM arises from the need to individualize medication regimens due to patient variability in drug absorption, distribution, metabolism, and excretion. Applications of TDM primarily include drugs with narrow therapeutic ranges, such as anticonvulsants, antibiotics, and immunosuppressants, and are crucial in personalized medicine, ensuring effective treatment while reducing adverse effects. The end-use scope primarily extends to hospitals, laboratories, and clinical settings [pharmacokinetic units], actively engaged in increasing treatment efficacy and safety. The market growth of TDM is influenced by factors such as the rising prevalence of chronic diseases, advancements in pharmacogenomics, and an increased focus on personalized medicine; however, challenges such as the high cost of testing, strict regulatory frameworks, and the need for skilled professionals could hamper growth. Moreover, TDM presents potential opportunities with innovations in point-of-care testing and the integration of AI for predictive monitoring, creating avenues for real-time drug monitoring and improving patient outcomes. To leverage these opportunities, stakeholders should invest in research and development to create cost-effective TDM solutions, fostering strategic partnerships with biotech firms and healthcare facilities to broaden their reach and adaptability. While market limitations include technological limitations and a lack of awareness in undeveloped regions, advancements in non-invasive sampling and rapid diagnostic techniques could significantly surmount these challenges. The most promising areas for innovation encompass developing portable and user-friendly monitoring devices and enhancing data analytics capabilities to deliver more precise and actionable insights. Overall, a strategic focus on innovation, affordability, and patient-centric solutions would be paramount for sustained market growth and capturing emerging opportunities in the dynamic field of Therapeutic Drug Monitoring.

KEY MARKET STATISTICS
Base Year [2023] USD 3.79 billion
Estimated Year [2024] USD 4.38 billion
Forecast Year [2030] USD 10.78 billion
CAGR (%) 16.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Drug Monitoring Market

The Therapeutic Drug Monitoring Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased Demand for Personalized Medicine
    • Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
    • Growing Use and Importance in Patients with Solid Organ Transplantation
  • Market Restraints
    • Inadequate Reimbursement Policies
    • Need of High Capital Investments
  • Market Opportunities
    • Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
    • Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
  • Market Challenges
    • Clinical Challenges and Limited Availability of Skilled Laboratory Technicians

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Drug Monitoring Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Drug Monitoring Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Drug Monitoring Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Drug Monitoring Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Drug Monitoring Market

A detailed market share analysis in the Therapeutic Drug Monitoring Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Drug Monitoring Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Drug Monitoring Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Drug Monitoring Market, highlighting leading vendors and their innovative profiles. These include apDia Group, Cambridge Life Sciences Limited, Danaher Corporation, ARK Diagnostics, Inc., Assay Genie, DiaSorin SpA, Merck KGaA, Grifols, S.A., Siemens Healthineers AG, Cardinal Health, Inc., Pfizer Inc., DiaSystem Scandinavia AB, R-Biopharm AG, Bio-Rad Laboratories, Inc., Krishgen Biosystems, H.U. Group Holdings, Inc., Buhlmann Laboratories AG, Myriad Genetics, Inc., Theradiag SA, Randox Laboratories, Ltd., Thermo Fisher Scientific, Inc., Tecan Trading AG, OneCare Media, LLC, Chromsystems Instruments & Chemicals GmbH, Agilent Technologies, Inc., Eagle Biosciences, Inc., Svar Life Science AB, Sekisui Chemical Co Ltd., Neoteryx, LLC by Trajan Group, Veolia Group, bioMerieux SA, ARUP Laboratories, Abbott Laboratories, F. Hoffmann-La Roche AG, and Exagen Inc..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Drug Monitoring Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Data Management Services, and Equipment. The Equipment is further studied across Chromatography & MS Detectors, Clinical Chemistry Analyzers, and Immunoassay Analyzers.
  • Based on Technology, market is studied across Chromatography-MS, Immunoassays, and Proteomic Technologies. The Chromatography-MS is further studied across GC-MS and LC-MS. The Immunoassays is further studied across Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, and Radioimmunoassays.
  • Based on Drug Class, market is studied across Antiarrhythmic Drugs, Antibiotic Drugs, Antiepileptic Drugs, Bronchodilator Drugs, Immunosuppressant Drugs, and Psychoactive Drugs.
  • Based on End-User, market is studied across Hospital Labs and Private Labs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased Demand for Personalized Medicine
      • 5.1.1.2. Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
      • 5.1.1.3. Growing Use and Importance in Patients with Solid Organ Transplantation
    • 5.1.2. Restraints
      • 5.1.2.1. Inadequate Reimbursement Policies
      • 5.1.2.2. Need of High Capital Investments
    • 5.1.3. Opportunities
      • 5.1.3.1. Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
      • 5.1.3.2. Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Clinical Challenges and Limited Availability of Skilled Laboratory Technicians
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for data management services for efficient drug management
    • 5.2.2. End-User: Increasing demand from hospitals where accurate drug management is essential
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Therapeutic Drug Monitoring Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Data Management Services
  • 6.4. Equipment
    • 6.4.1. Chromatography & MS Detectors
    • 6.4.2. Clinical Chemistry Analyzers
    • 6.4.3. Immunoassay Analyzers

7. Therapeutic Drug Monitoring Market, by Technology

  • 7.1. Introduction
  • 7.2. Chromatography-MS
    • 7.2.1. GC-MS
    • 7.2.2. LC-MS
  • 7.3. Immunoassays
    • 7.3.1. Chemiluminescence Immunoassays
    • 7.3.2. Colorimetric Immunoassays
    • 7.3.3. Fluorescence Immunoassays
    • 7.3.4. Radioimmunoassays
  • 7.4. Proteomic Technologies

8. Therapeutic Drug Monitoring Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Antiarrhythmic Drugs
  • 8.3. Antibiotic Drugs
  • 8.4. Antiepileptic Drugs
  • 8.5. Bronchodilator Drugs
  • 8.6. Immunosuppressant Drugs
  • 8.7. Psychoactive Drugs

9. Therapeutic Drug Monitoring Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospital Labs
  • 9.3. Private Labs

10. Americas Therapeutic Drug Monitoring Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Therapeutic Drug Monitoring Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Drug Monitoring Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Capitainer announces collaboration with AstraZeneca.
    • 13.3.2. Novo Holdings invests in proteomics technology company, Evosep.
    • 13.3.3. AegirBio AB enters into an agreement with Atlas Special Opportunities, LLC regarding convertible bonds of SEK 55 million with attached warrants to intensify investments in i.a. TDM and saliva sampling.
    • 13.3.4. Clinical LC-MS methods for therapeutic drug monitoring analysis.
    • 13.3.5. Boditech Med has obtained the export license of four TDM products.
    • 13.3.6. Pace Obtains EPA Approval on Method for Detecting Dioxins and Dibenzofurans Through GC-MS/MS Technology.
    • 13.3.7. Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring.
    • 13.3.8. Beckman Coulter and Saladax Biomedical Team Up on Antipsychotic Therapeutic Drug Monitoring.
    • 13.3.9. Ampersand Capital Partners Invests in Syft Technologies, Leading SIFT-MS Solutions Provider.

Companies Mentioned

  • 1. apDia Group
  • 2. Cambridge Life Sciences Limited
  • 3. Danaher Corporation
  • 4. ARK Diagnostics, Inc.
  • 5. Assay Genie
  • 6. DiaSorin SpA
  • 7. Merck KGaA
  • 8. Grifols, S.A.
  • 9. Siemens Healthineers AG
  • 10. Cardinal Health, Inc.
  • 11. Pfizer Inc.
  • 12. DiaSystem Scandinavia AB
  • 13. R-Biopharm AG
  • 14. Bio-Rad Laboratories, Inc.
  • 15. Krishgen Biosystems
  • 16. H.U. Group Holdings, Inc.
  • 17. Buhlmann Laboratories AG
  • 18. Myriad Genetics, Inc.
  • 19. Theradiag SA
  • 20. Randox Laboratories, Ltd.
  • 21. Thermo Fisher Scientific, Inc.
  • 22. Tecan Trading AG
  • 23. OneCare Media, LLC
  • 24. Chromsystems Instruments & Chemicals GmbH
  • 25. Agilent Technologies, Inc.
  • 26. Eagle Biosciences, Inc.
  • 27. Svar Life Science AB
  • 28. Sekisui Chemical Co Ltd.
  • 29. Neoteryx, LLC by Trajan Group
  • 30. Veolia Group
  • 31. bioMerieux SA
  • 32. ARUP Laboratories
  • 33. Abbott Laboratories
  • 34. F. Hoffmann-La Roche AG
  • 35. Exagen Inc.

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC DRUG MONITORING MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC DRUG MONITORING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. THERAPEUTIC DRUG MONITORING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. THERAPEUTIC DRUG MONITORING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC DRUG MONITORING MARKET DYNAMICS
  • TABLE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GC-MS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LC-MS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RADIOIMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PROTEOMIC TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY BRONCHODILATOR DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PSYCHOACTIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZ